Patterns of multiple primary tumours in patients treated for cancer during childhood

Kingston, J. E.; Hawkins, Mike; Draper, G J; Marsden, H. B.; Wilson, Lisa

doi:10.1038/bjc.1987.199

Cited by 94 publications

(43 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Several reports have established a causal relation between the occurrence of multiple malignancies and a genetic syndrome in children with primary brain tumors. 2,3,10,12,13 The relation between NF1 and subsequent neoplasms has been well documented, although the impact of intervening therapies is less well established. A small number of case reports and only two series have demonstrated this relation with respect to syndromes other than NF1.…”

Section: Discussionmentioning

confidence: 99%

“…A small number of case reports and only two series have demonstrated this relation with respect to syndromes other than NF1. 3,13,[22][23][24] Kingston et al reported that a genetic condition other than NF1 was present in 5 of 45 children (11%) with primary CNS tumors who later experienced an SN; 3 of those patients had Gorlin syndrome, 1 patient had Turcot syndrome, and 1 patient had tuberous sclerosis. 3 In the other series, two patients with Gorlin syndrome were among the four patients overall who developed an SN.…”

Section: Discussionmentioning

confidence: 99%

“…It is well recognized that children with NF1 have an increased risk of developing an SN and, in particular, a second brain tumor. 2,3,10,12 The risk of developing a second brain tumor for children with NF1 and an optic pathway glioma is estimated to be between 11% and 52%. 26 -28 The rigorous histologic and radiologic review performed in the current series allowed the exclusion of patients with tumor recurrence or anaplastic progression of low-grade glioma.…”

Section: Discussionmentioning

confidence: 99%

“…Patients who had a diagnosis of neurofibromatosis type 1 (NF1) were excluded from the study because of their known predisposition toward developing SNs. 2,3,10,12 …”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Second neoplasms in pediatric patients with primary central nervous system tumors

Broniscer¹,

Ke²,

Fuller³

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUNDDetails on second neoplasms (SNs) following pediatric central nervous system (CNS) tumors are scant, because of the rarity of such SNs. The goal of the current study was to investigate and characterize these rare SNs.METHODSThe authors reviewed clinical and treatment data on all institutional patients age < 22 years at diagnosis of a primary CNS tumor who developed any type of SN. Patients with neurofibromatosis type 1 were excluded. Cumulative incidence rates were estimated, and putative risk factors were analyzed.RESULTSThe SNs investigated in the current study included 10 gliomas (42%), 5 meningiomas (21%), 2 desmoid tumors, 2 myelodysplastic syndromes, 2 basal cell carcinomas, 1 leukemia, 1 malignant fibrous histiocytoma, and 1 thyroid carcinoma. Twenty‐one patients had previously received radiotherapy, and 12 patients had received chemotherapy. The SN was related to a genetic cause in 7 patients (29%). Eleven patients died of their SNs, including 8 patients with glioma and 2 patients with myelodysplastic syndromes. The estimated 15‐year cumulative incidence rate for malignant SNs was 4%. Children with choroid plexus tumors had an estimated 10‐year cumulative incidence rate of 20.2%; 2 of those patients had germline TP53 mutations. Age ≤ 2 years was a significant risk factor (P = 0.016) for development of an SN only when patients with genetic conditions were included in the analysis. No significant difference in the estimated cumulative incidence of SNs was found among patients who had received different types of therapy.CONCLUSIONSThe risk of lethal SNs after pediatric CNS tumors is small. Young patients and patients with choroid plexus tumors appear to have an increased risk of SNs that is associated with genetic factors. Cancer 2004. © 2004 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Patients who had a diagnosis of neurofibromatosis type 1 (NF1) were excluded from the study because of their known predisposition toward developing SNs. 2,3,10,12 …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Second neoplasms in pediatric patients with primary central nervous system tumors

Broniscer¹,

Ke²,

Fuller³

et al. 2004

Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, the MRI scan did not reveal typical signs of intracranial metastases; therefore, we treated this patient as if the intracranial tumor was a primary glioma, a diagnosis that was confirmed by postoperative pathological results. Although, there are some reports suggesting that intracranial tumors can occur as secondary primary malignancies [4,7,8], the shortest interval between the two malignancies was greater than 12 months [8]. However, the interval in our case was only two months, and the patient did not undergo any radiotherapy or chemotherapy during this period.…”

Section: Discussionmentioning

confidence: 43%

An Intracranial Tumor Appeared Two Months after the Operation of Bladder Cancer: Metastatic or Primary?

Zhao¹

2017

JNSK

View full text Add to dashboard Cite

It is common for an intracranial mass to occur after another malignancy, which is usually metastasis. There are also reports that intracranial tumors have appeared years after another carcinoma had been previously treated with radiotherapy or chemotherapy. In the latter case, the intracranial tumor is usually attributed to metastasis or a secondary primary malignancy. There are also some hereditary or familial syndromes that present with multiple tumors, e.g., Li Fraumeni, Lynch, and Turcot syndrome. For these syndromes, the proband cancer generally occurs in children and young adults with a definitive familial aggregation. However, we found no previous reports of the appearance of a primary glioma only 2 months after a bladder cancer carcinectomy in an old patient without a typical family history. Here, we report the case of a 59-year-old female who complained of a constant headache for one week at the time of admission. Only 2 months before, she had undergone a bladder cancer carcinectomy. Upon admission, a cranial MRI scan revealed right temporal lobe lesions, and the post-operative pathological diagnosis was anaplastic astrocytoma. Cases such as these are easily misdiagnosed, and the opportunity for surgical treatment can be lost. Moreover, the appearance of two concurrent cancers or the occurrence of one after another within a very short interval in different body parts has rarely been reported. Therefore, this case may provide neurosurgeons with knowledge of an uncommon clinical experience that could reduce misdiagnosis and mistreatment.

show abstract

Hyperfractionated External Beam Radiation Therapy in the Treatment of Murine Transgenic Retinoblastoma

Hayden¹,

Murray

Cicciarelli

et al. 2002

Arch Ophthalmol

View full text Add to dashboard Cite

Objective: To determine the in vivo efficacy of hyperfractionated external beam radiation therapy (EBRT) in comparison with standard daily EBRT in a murine model of heritable retinoblastoma. Methods: Two hundred twenty eyes from 6-week-old simian virus-40 large T-antigen-positive mice were treated with a total dose of EBRT ranging from 10-76 Gy (1000 to 7600 rad). One hundred ten eyes underwent EBRT administered in 2.0-Gy (200-rad) fractions once per day. Forty-two eyes received hyperfractionated EBRT administered in 1.2-Gy (120-rad) fractions twice per day, while 48 eyes received EBRT twice daily in fractions of 5.0 Gy (500 rad). Twenty eyes served as untreated controls. All eyes were obtained for histopathologic examination and graded positive if any tumor was present. Results: A dose-dependent inhibition of ocular tumor was observed for EBRT in these transgenic retinoblastoma mice. The tumor control dose for 50% of eyes (TCD 50) treated with 2.0 Gy fractions of EBRT was 45 Gy (4500 rad) when treatments were administered once daily. A significant increase in tumor control was observed when treatments were administered twice per day at fractions of 1.2 Gy, resulting in a TCD 50 of 33 Gy (3300 rad) (P=.003). A further increase in tumor control was observed when twice-daily EBRT was administered in 5.0 Gy fractions resulting in a TCD 50 of 28 Gy (2800 rad). Conclusions: Hyperfractionated EBRT safely and effectively controls intraocular retinoblastoma in this transgenic animal model. Use of hyperfractionation allows for a reduction in total radiation delivered dose, while shortening the total treatment time. Clinical Relevance: This treatment approach may be applicable in the management of pediatric retinoblastoma by maintaining excellent tumor control, while reducing treatment-associated complications.

show abstract

Patterns of multiple primary tumours in patients treated for cancer during childhood

Cited by 94 publications

References 34 publications

Second neoplasms in pediatric patients with primary central nervous system tumors

Second neoplasms in pediatric patients with primary central nervous system tumors

An Intracranial Tumor Appeared Two Months after the Operation of Bladder Cancer: Metastatic or Primary?

Hyperfractionated External Beam Radiation Therapy in the Treatment of Murine Transgenic Retinoblastoma

Contact Info

Product

Resources

About